Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Aronson

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Life Sciences|January 1, 1991
Gossypol effects on endothelial cells and tumor blood flowC C Benz, S B Iyer, H S Asgari, et al.
AJR. American Journal of Roentgenology|February 1, 1991
Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patientsR R Saxon, J S Klein, M H Bar, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomasF H Valone, D R Gandara, A B Deisseroth, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Life Sciences|January 1, 1991
Gossypol effects on endothelial cells and tumor blood flowC C Benz, S B Iyer, H S Asgari, et al.
AJR. American Journal of Roentgenology|February 1, 1991
Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patientsR R Saxon, J S Klein, M H Bar, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomasF H Valone, D R Gandara, A B Deisseroth, et al.
Blood|November 15, 1990
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effectsJ W Mier, G Vachino, M S Klempner, et al.
Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effectsJ A Sosman, G R Weiss, K A Margolin, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of the National Cancer Institute|September 5, 1990
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaE R Gaynor, G R Weiss, K A Margolin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Pageof 3